The use of nebulised frusemide in Australian palliative care

1. Background to this survey

Dear colleague

Thank you for taking the time to complete this survey. This study will have been explained to you in the email providing the link to this survey.

The use of nebulised frusemide has been proposed for dyspnoea, and is currently prescribed by some palliative care clinicians. Currently, there is not robust evidence to support or refute this practice.

This brief online survey will collect information about the current use of nebulised frusemide by Australian palliative care clinicians.

We would very much appreciate your time in completing the survey, which should take about 10 minutes. If you are interested in receiving further information about nebulised frusemide, you can provide your email address at the end of the survey and additional survey will be sent to you.

We are also interested in obtaining your views of this method of using brief online surveys as a way to collect information about prescribing practices in palliative care.

This survey is being undertaken by ImPACCT (Improving Palliative Care through Clinical Trials) which is the New South Wales (NSW) collaborative clinical trials group in palliative care

Information from this survey will assist us in planning future clinical trials.

Dr Christine Sanderson
Dr Phillip Newton
Professor Patricia Davidson
for ImPaCCT (Improving Palliative Care through Clinical Trials)

The use of nebulised frusemide in Australian palliative care

1. Participant Consent Statement

Ethics approval No: SON&M12-2010

Chief Investigators: Dr Christine Sanderson, Dr Phillip Newton, Professor Patricia Davidson for NSW Palliative Care Clinical Trials Collaborative Research Group (ImPACCT)

I am making a decision to voluntarily participate in the research project named above. By ticking the box below I indicate that I have read and understood the 'Participant Information Sheet' provided.

I understand that:

- 1. Participation involves completing an on-line questionnaire which will take approximately 5-10 minutes to complete
- 2. I can withdraw from the study at any time by contacting Dr Christine Sanderson on 02 95533111

(telephone) or christinersanderson@gmail.com

My withdrawal will not in any way affect my relationship with the study investigators.

- 3. If you have any concerns about the way in which this research is being conducted, you may contact the Manager, Research Ethics at Curtin University of Technology on (08)92662784 quoting Curtin University Ethics Approval Number: SON&M12-2010
- 4. The research study is strictly confidential and no information about me will be used in any way that reveals my identity
 - I hereby agree to participate in this research study
 - O I do not wish to participate in this study

2. Some information about you

This section is designed to obtain some information regarding your professional status

The	use of nebulised frusemide in Australian palliative care
*1	I. Your current role is
0	General practitioner
0	Resident medical officer working in palliative care
0	Career medical officer working in palliative care
0	Palliative care consultant
0	Paliative care registrar
0	Other (please specify)
2. V	What is your highest qualification in palliative care?
0	No formal qualification
0	Clinical diploma
0	Advanced trainee in palliative care
0	Master of palliative care
0	Fellow of the Chapter of Palliative Medicine and/or FRACP
0	Dual fellowship: Fellowship of Royal Australasian College of Physicians with Advanced training in both Palliative Medicine and
Med	lical Oncology
*3	3. How many years of palliative care experience do you have?
4. V	Nhere do you work?
0	New Zealand
0	Queensland
0	New South Wales
0	ACT
0	Victoria
0	Tasmania
0	South Australia
0	Northern Territory
0	Western Australia
2 N	lebulised frusemide use
J. N	iebulisea Trusemiae use
*1	I. Have you prescribed nebulised frusemide for dyspnoea in the last 12 months?
0	Yes
0	No
4. If	you have not prescribed nebulised frusemide

/e	are interested in exploring your reasons for not using nebulised frusemide
. I	f you have not used nebulised frusemide in the last 12 months, please tick all of th
oll	owing reasons why you have not done so
0	Have never heard of administering frusemide via the nebulised route
0	Aware of the potential of administration but not familiar enough with procedure and dosages
0	Believe there is not enough evidence for nebulised frusemide
0	Have used it previously and not been convinced of its effectiveness
0	Have used it and noted adverse effects or other problems (please describe)
	Please provide any other information that may explain why you have not used
ah	
eb	pulised frusemide in the last 12 months.
eb	
. N	ebulised frusemide in the last 12 months.
. N	oulised frusemide in the last 12 months.
. N	ebulised frusemide in the last 12 months. lebulised frusemide prescribing f you have used nebulised frusemide- what is your perception of its use in relievin
N lys	debulised frusemide in the last 12 months. In the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months.
N lys	debulised frusemide in the last 12 months. In the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months. It is a second of the last 12 months.
N N lys	debulised frusemide in the last 12 months. In the last 12 months. It is provided by the last 12 months.
l. I	debulised frusemide in the last 12 months. I ebulised frusemide prescribing If you have used nebulised frusemide- what is your perception of its use in relieving spaces I no use I some use I unsure
l. I	debulised frusemide prescribing f you have used nebulised frusemide- what is your perception of its use in relieving spnoea no use some use unsure useful very useful
N ys	debulised frusemide in the last 12 months. In the last 12 months. It is pour perception of its use in relieving spinoea on use some use unsure useful
N . I . ys	debulised frusemide in the last 12 months. Separate debulised frusemide prescribing Fryou have used nebulised frusemide- what is your perception of its use in relieving spnoea no use some use unsure useful very useful What do you think should be the place of nebulised frusemide in treatment?
N . I . Y	debulised frusemide in the last 12 months. Idebulised frusemide prescribing If you have used nebulised frusemide- what is your perception of its use in relieving spnoea In ouse In

	. What frequency of administration do you prescribe nebulised frusemide? (select
II t	hat apply)
	Daily
	Twice daily
	Three times daily
	Four times daily
	PRN
	Other (please specify)
* 4,	. What dose of nebulised frusemide do you normally prescribe? (select all that
app	
	20 mg
	30 mg
	40 mg
	60 mg
	80 mg
	Other (please specify)
. G	ase A
Plea	se try to recall the last two patients you prescribed nebulised frusemide for and describe them below.
	ne
	ge
1. A	
1. A	ender
1. A	ender Male
1. A	ender Male Female
1. A	ender Male
1. A	ender Male Female
1. A	ender Male Female iagnosis lain problem causing dyspnoea (please be as precise as possible, eg pulmonary
1. Ag 2. G 3. D	ender Male Female iagnosis
1. Ag 2. G 3. D 4. M	ender Male Female iagnosis lain problem causing dyspnoea (please be as precise as possible, eg pulmonary

The	use of nebulised frusemide in A	usti	ralian palliative care
6. C	Other treatments already tried for dyspno	ea:	
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		
7. P	Please select any other treatments co-pre	escr	ibed with nebulised frusemide:
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		
	Obvious improvement associated with use of nebulised frusemic Possible improvement associated with use of nebulised frusemic No improvement other comments (for instance - time to onset of effect, duration of	de	fect, any adverse effects, or problems with administration)?
	Y		
7. C	ase B		
1. A	Age Gender		
0	Male		
0	Female		
3. [Diagnosis		
91 L			
		-	

E 1	Main comorbidities		
J. 1	walli Collioi biuities		
6. (Other treatments already tr	ied for dyspnoea:	
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		
7. I	Please select any other trea	tments co-prescri	bed with nebulised frusemide:
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		
3. (Clinical impression of effec	tiveness in this ca	se:
	Obvious improvement associated with use	of nebulised frusemide	
	Possible improvement associated with use	e of nebulised frusemide	
	No improvement		
Any	other comments (for instance - time to onse	et of effect, duration of the eff	ect, any adverse effects, or problems with administration)?
		A	
	Some brief comments o	4bio	
_		* = 1 * 1 (= 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

The use of nebulised frusemide in Australian palliative care

palliative care practice? C not important Somewhat important important very important very important 2. How difficult was this survey to complete? C not difficult at all a bit difficult very useful at all somewhat useful very useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult very difficult very difficult very difficult ifficult ifficult representation very difficult v	1. H	low important do you think it is to obtain information about drug prescribing in
comportant very important very important 2. How difficult was this survey to complete? ont difficult at all a bit difficult difficult very difficult very difficult very difficult somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult was for you to recall the information? If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somewhat likely likely likely	pal	liative care practice?
c important c very important 2. How difficult was this survey to complete? c not difficult at all a bit difficult difficult very difficult very difficult 3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? not useful at all somewhat useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult difficult or very difficult reserved in the information? If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely likely	0	not important
2. How difficult was this survey to complete? ont difficult all a bit difficult difficult very difficult very difficult very difficult not useful at all somewhat useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult somewhat difficult difficult very difficult somewhat difficult not difficult livery difficult representation 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	somewhat important
2. How difficult was this survey to complete? C not difficult at all a bit difficult very difficult very difficult very difficult not useful at all somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult outficult somewhat difficult outficult very difficult	0	important
c not difficult at all c a bit difficult difficult very difficult 3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? not useful at all somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult rease provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	very important
c a bit difficult c difficult very difficult 3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? not useful at all somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult very difficult output not difficult very difficult	2. F	low difficult was this survey to complete?
C difficult 3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? C not useful at all C somewhat useful C useful V very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? C did not complete case study C not difficult C somewhat difficult D difficult V very difficult V very difficult V very difficult V rey difficu	0	not difficult at all
3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? on tuseful at all somewhat useful useful very useful If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? old do not complete case study not difficult somewhat difficult difficult very difficult very difficult lease provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	a bit difficult
3. Do you think the method of an on-line survey is useful to identifying prescribing patterns? ont useful at all somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? old do not complete case study not difficult somewhat difficult very difficult very difficult very difficult very difficult not difficult very difficult	0	difficult
patterns? C not useful at all somewhat useful very useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	very difficult
C not useful at all somewhat useful useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult lease provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	3. [Oo you think the method of an on-line survey is useful to identifying prescribing
c somewhat useful c useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? c did not complete case study not difficult somewhat difficult very difficult very difficult lease provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	pat	terns?
 useful very useful 4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult very difficult recessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	0	not useful at all
4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	somewhat useful
4. If you completed the case studies as part of this survey please identify how difficult it was for you to recall the information? c did not complete case study not difficult difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	useful
was for you to recall the information? did not complete case study not difficult somewhat difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely	0	very useful
 did not complete case study not difficult somewhat difficult very difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	4. I	f you completed the case studies as part of this survey please identify how difficult it
 not difficult somewhat difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	wa	s for you to recall the information?
 somewhat difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	0	did not complete case study
 difficult very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	0	not difficult
 very difficult Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? not likely at all somehat likely likely 	0	somewhat difficult
Please provide comments if necessary 5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? onot likely at all somehat likely likely	0	difficult
5. If you were asked to participate in a survey of this type in the future, how likely would you be to participate? one not likely at all osomehat likely likely	0	very difficult
you be to participate? onot likely at all osomehat likely likely	Plea	se provide comments if necessary
you be to participate? Onot likely at all Osomehat likely Ilikely		
you be to participate? onot likely at all osomehat likely likely	5. I	f you were asked to participate in a survey of this type in the future, how likely would
Somehat likely likely		
O likely	0	not likely at all
	0	somehat likely
O very likely	0	likely
	0	very likely

*6. Are you wil	oulised frusemide in Australian palliative care
•	ling in help us validate the accuracy of the case studies described?
C I did not describe ar	ny cases
C No	
C Yes	
9. Case study v	validation
	assessing the accuracy of the case studies described by asking you to review the clinical notes ribed and complete the same questions.
If you are interested of the page.	in completing this section, simply press the "Exit this survey" button in the top right hand corner
	clinical notes, click on the link in the email that you received to start this survey and you will be page and will be able to answer the remaining questions.
10. Case A - no	tes reviewed
Please complete the	following questions based after you have reviewed the clinical notes
·	Tollowing questions based after you have reviewed the difficult following
1. Age	
2. Gender	
○ Male	
C Female	
3. Diagnosis	
-	causing dyspnoea (please be as precise as possible, eg pulmonary iac failure, or pleural effusion, etc etc) dities
fibrosis, or cardi	ac failure, or pleural effusion, etc etc)
fibrosis, or cardi	ac failure, or pleural effusion, etc etc)
fibrosis, or cardi	dities
5. Main comorbi	dities ents already tried for dyspnoea:
5. Main comorbio 6. Other treatme	dities ents already tried for dyspnoea:
5. Main comorbio 6. Other treatme Oxygen Opioids	dities ents already tried for dyspnoea: Antibiotics Non-invasive ventilation
fibrosis, or cardi 5. Main comorbio 6. Other treatme Oxygen Opioids Steroids	dities ents already tried for dyspnoea: Antibiotics Non-invasive ventilation None

7. F		
	Please select any other treatments co	p-prescribed with nebulised frusemide:
	Oxygen	☐ Antibiotics
	Opioids	☐ Non-invasive ventilation
	Steroids	None
	Benzodiazepines	Can not recall
	Bronchodilators	
	Other (please specify)	
8. 0	Clinical impression of effectiveness in	n this case:
	Obvious improvement associated with use of nebulised fru	usemide
	Possible improvement associated with use of nebulised fru	usemide
	No improvement	
eff pat	<u> </u>	es to support answer regarding clinical per of breakthroughs, documented comments by sults for the symptom)?
0	Yes (please specify)	verse events related to nebulised frusemide
0	Yes (please specify) . Was there any documentation of adv	verse events related to nebulised frusemide
10.	Yes (please specify) . Was there any documentation of adv	verse events related to nebulised frusemide
10. use	Yes (please specify) . Was there any documentation of adverge?	verse events related to nebulised frusemide
10. use	Yes (please specify) . Was there any documentation of adverage? No	verse events related to nebulised frusemide
10. use	Yes (please specify) . Was there any documentation of adverage? No	verse events related to nebulised frusemide
10. use o	Yes (please specify) . Was there any documentation of adverage? No Yes (please specify)	

	Male Female		
8. D	Diagnosis		
	Nain problem causing dyspnosis, or cardiac failure, or plo		ns precise as possible, eg pulmonar c etc)
5. N	lain comorbidities		
S. C	Other treatments already trie	ed for dyspnoea:	
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		
7. P	lease select any other treat	ments co-prescri	bed with nebulised frusemide:
	Oxygen		Antibiotics
	Opioids		Non-invasive ventilation
	Steroids		None
	Benzodiazepines		Can not recall
	Bronchodilators		
	Other (please specify)		

The use of nebulised frusemide in Australian palliative care	
9. Was there any evidence from the notes to support answer regarding clinical	
effectiveness (eg reduction in the number of breakthroughs, documented comments by patient or other team members, SAS results for the symptom)?	
O No	
C Yes (please specify)	
10. Was there any documentation of adverse events related to nebulised frusemide	
use?	
O No	
C Yes (please specify)	
12. Are you interested in participating in an email group?	
Subscribing to this email list will allow access to further information regarding nebulised frusemide and in the future potential opportunities to participate in clinical studies.	!
Please provide your email address or if you want to provide your contact details	
seperate to this questionnaire please email phillip.newton@uts.edu.au	